• PDF / 170,985 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 14 Downloads / 161 Views

DOWNLOAD

REPORT

---

1 S

Various toxicities: 10 case reports In a retrospective study of 26 patients, who were treated between October 2014 and October 2018, 10 patients including 8 men and a woman aged 45-77 years [not all ages and sexes stated] were described, who developed aspartate aminotransferase elevation, alanine aminotransferase elevation, blood bilirubin elevation and arthralgia, neutropenia, aspartate aminotransferase elevation and colitis, type 1 diabetes mellitus, myalgia, increase in viral load or immune-related hepatitis following treatment with atezolizumab, ipilimumab, mesalazine, nivolumab, pembrolizumab, sulfasalazine for non-small cell lung cancer or ulcerative colitis [routes and dosages not stated]. All patients were diagnosed with non-small cell lung cancer. One patient had ulcerative colitis and receiving treatment with mesalazine [mesalamine] and sulfasalazine. Their medical history included liver metastases, hepatitis B virus infection, hepatitis C virus infection or hepatitis B and hepatitis C virus infection. Four patient had concurrent conditions including cirrhosis due to alcoholism, HIV or alcoholism and the patient with HIV infection was receiving unspecified ART for HIV infection. Three patient had grade 1 abnormality in aspartate aminotransferase or alanine aminotransferase. All the patients started receiving immune therapy with ipilimumab and nivolumab, pembrolizumab or atezolizumab for non-small cell lung cancer. Pembrolizumab was given as first line therapy (4 patients) and second line therapy (2 patients), ipilimumab and nivolumab were given as first line therapy (1 patient), atezolizumab was given as second line therapy (1 patient) and unspecified line of therapy (1 patient), and nivolumab was given as fifth line therapy(1 patient). Two patients were receiving concomitant medications including pemetrexed, carboplatin or tenofovir. Subsequently, they developed immunotherapy related adverse effects including grade 1 aspartate aminotransferase elevation secondary to first line therapy with pembrolizumab (2 patients), grade 1 alanine aminotransferase elevation secondary to first line therapy with ipilimumab and nivolumab (1 patient), grade 4 neutropenia secondary to mesalazine, sulfasalazine and second line therapy with pembrolizumab (1 patient), grade 1 aspartate aminotransferase elevation and grade 3 colitis secondary to second line therapy with atezolizumab (1 patient), grade 3 type 1 diabetes mellitus secondary to second line therapy with pembrolizumab (1 patient), grade 2 blood bilirubin elevation and grade 2 arthralgia secondary to first line therapy with pembrolizumab (1 patient), grade 1 myalgia secondary to first line therapy with pembrolizumab (1 patient), increase in viral load secondary to fifth line therapy nivolumab (1 patient) who had hepatitis B virus infection and immune-related hepatitis secondary to atezolizumab (1 patient). The patient, who developed diabetes, progressed to grade 3 diabetic ketoacidosis. In the patient, who developed grade 4 neutropenia, the pembrolizumab therapy